Slt Antineoplastics that Prolong QT/Strong CYP3A4 Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Your medicine may slow down how quickly your body processes your cancer medicine.

What might happen:

The amount of cancer medicine in your blood may increase and cause more side effects than expected and some expected side effects to be more severe.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicine or the timing of your cancer medicine.Let your doctor know right away if you experience nausea, vomiting, abdominal pain (especially in the right upper area of your abdomen), yellowing of the eyes or skin, dark urine, itching, loss of appetite, shortness of breath, coughing, swelling of the ankles/legs, rapid/fast/irregular heartbeat, dizziness, loss of consciousness,or if you gain more than 5 pounds in 24 hours.Let your doctor know if you have an increase in diarrhea, nausea, stomach upset, or vomiting; if you have any unusual bleeding; if you have any chest pain or pressure, numbness or weakness on one side or your body, trouble talking, or severe headache; if you have any swelling, weight gain, or shortness of breath; have a fever; develop an increased thirst, urinate more often than normal, or if your breath smells like fruit; develop eye pain/swelling/redness or blurred vision or other vision changes; or if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. November 18, 2018.
  • 2.Zykadia (ceritinib) US prescribing information. Novartis Pharmaceuticals Corporation March, 2019.
  • 3.Xalkori (crizotinib) US prescribing information. Pfizer Inc. June, 2019.
  • 4.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company November 19, 2017.
  • 5.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline December, 2018.
  • 6.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation March, 2018.
  • 7.Votrient (pazopanib) US prescribing information. GlaxoSmithKline May, 2017.
  • 8.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. May, 2019.
  • 9.Fareston (toremifene citrate) US prescribing information. GTx, Inc. March, 2011.
  • 10.Javlor (vinflunine ditartrate) UK Summary of Product Characteristics. Pierre Fabre Limited September 21, 2009.
  • 11.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
  • 12.Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther 2012 Sep;34(9):2011-9.e1.
  • 13.Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011 Dec;51(12):1721-7.
  • 14.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and -drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
  • 15.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2019..

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.